«Double-hit» лимфома с первичным поражением молочной железы: собственное наблюдение и обзор литературы

1. Aukema SM, Siebert R, Schuuring E, van Imhoff  GW, Kluin-Nelemans  HC, Boerma E-J, Kluin PM. Double-hit B-cell lymphomas. Blood. 2011 (24 February);  117(8).
2. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. IARC, Lyon, 2016. 
4. Zhou K, Xu D, Cao Y, Wang J, Yang Y, Huang M, C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. PLoS One. 2014; 9(4):e95020. 
5. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y & Miura I. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009; 94, 935-943. 
6. Horn H, Ziepert M, Becher C et al., MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121(12):2253-63. 
7. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L et al., Double-hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014; 166:891-901. 
8. de Jongea AV,  Roosmaa TJA,  Houtenbosb I,  Vasmeld WLE,  van de Heme K,   de Boerf  JP, van Maaneng T, Lindauer-van der Werfh G, Beekerc A, Timmersi GJ, Schaarj CG, Soesank M, Poddighel PJ, de Jongm D. M.E.D., Chamuleaua.  Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature. European Journal of Cancer. 2016; 55: 140-146. 
9. Petrich AM, Gandhi M, Jovanovic B et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124 (15).
10. Sun H, Savage KJ, Karsan A et al. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Сlinical Lymphoma, Myeloma & Leukemia, 2015 June.
11. Cuccuini W, Briere J, Mounier N et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012; 119:4619-4624. 
12. Herrera AF, Mei M, Low L et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017; 35:24-31. 
13. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Kuppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014; 99:726-35.
14. Габеева Н.Г., Королева Д.А., Беляева А.В., Чернова Н.Г., Кузьмина Л.А., Судариков А.Б., Обухова Т.Н., Ковригина А.М., Звонков Е.Е., Савченко В.Г. Диффузная В-крупноклеточная лимфома с сочетанной реаранжировкой генов с-MYC и BCL-6 с первичным поражением кожи: собственное наблюдение и обзор литературы. Терапевтический архив. 2017; 89(7):85-92. [Gabeeva NG, Koroleva DA,  Beliaeva AV, Chernova NG, Kuzmina LA,  Sudarikov AB, Obuchova TN, Kovrigina AM, Zvonkov EE, Savchenko VG. Diffuse large B-cell lymphoma with concomitant  rearrangement of genes c-MYC and BCL-6 with primary cutaneous involvement: a case report  and review of literature. Terapevticheskii arkhiv. 2017; 89(7):85-92. (In Russ.)].
15. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T et al. and the Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB), MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98:1554-62.
16. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequencespecific transcriptional repressor. Proc Natl Acad Sci USA. 1996; 93:6947-6952.
17. Iqbal J, Greiner TC, Patel K, Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007 November; 21(11): 2332-2343.
18. Обухова Т.Н., Барях Е.А., Лорие Ю.Ю., Черныш С.А., Колошейнова Т.И., Петрова Г.Д., Нестерова Е.С., Римашевская Е.В., Семенова А.А., Магомедова А.У., Звонков Е.Е., Паровичникова Е.Н., Алимова Г.А., Клеина И.В., Ковригина А.М., Капланская И.Б., Воробьев И.А., Луговская С.А., Тупицын Н.Н., Кравченко С.К., Домрачева Е.В. «Double-hit" лимфомы. Гематология и трансфузиология. 2012; 57(S3): 17. [Obuchova TN, Barax EA, Lorie UU, Chernuch CA, Kolocheinova TI, Petrova GD, Nesterava EC, Rimachevskaia EV, Semenova AA, Magamedova AY, Zvonkov EE, Parovichnicova EN, Alimova GA, Kleina BD, Kovrigina AM, Kaplanskaia IB, Vorobov IA, Lugovskaia SA, Tupicin NN, Krafchenco CK, Domracheva EV. «Double-hit» lynphomas. Hematology and transfusiology. 2012; 57(S3):17. (In Russ.)].
19. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463: 88-92. 
20. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459:717-721. 
21. Wei-Ge Wang, Xiang-Nan Jiang, Ze-Bing Liu, Xiao-Yan Zhou, Xiao-Qiu Li,  MYC Protein–positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway. Am J Surg Pathol. 2017; 41(4). 
22. Wilson WH, Young RM et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature medicine. 2015; 21(8).
23. Younes A, Thieblemont C et al. Combination of ibrutinib with rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014; 15: 1019-26. 
24. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:1937-1947.
25. Johnson-Farley N, Veliz J, Bhagavathi S et al. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells. Leuk Lymphoma. 2015; 56:2146-2152.
26. Borthakur G, Dawson MA, Stein EM et al. A phase I/II openlabel, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies. Blood. 2016; 128:5223. 
27. Nabhan C, Karrison T, Kline J et al. Prospective phase I multicenter trial incorporating lenalidomide (LEN) into dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in patients with double hit (DHL) or double expressing (DEL) lymphomas: final results. Blood. 2016; 128:4191.
28. Lindsleya RC, LaCascea AS. Biology of Double-Hit B Cell Lymphomas. Curr Opin Hematol. 2012 July; 19(4):299-304.
29. Sarkozy C, Traverse-Glehen A, Coiffier B, Double-hit and double-protein-expression lymphomas:aggressive and refractory lymphomas. Lancet Oncol. 2015; 16: 555-67.
30. Чернова Н.Г., Звонков Е.Е., Ковригина А.М., Судариков А.Б., Бадмажапова Д.С., Габеева Н.Г., Обухова Т.Н., Карагюлян С.Р., Савченко В.Г. Ассоциированная с имплантатом анапластическая крупноклеточная лимфома молочной железы: описание клинического случая и обзор литературы. Терапевтический архив. 2017; 89(7): 93-98. [Chernova NG, Zvonkov EE, Kovrigina AM, Sudarikov AB, Badmazhapova DS, Gabeeva NG, Obukhova TN, Karagyulyan SR, Savchenko VG.  Breast implant-associated anaplastic large-cell lymphoma: A case report and a review of literature. Terapevticheskii arkhiv. 2017; 89(7):93-98. (In Russ.)].
31. Ryan GF1, Roos DR, Seymour JF. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma. 2006 Jan; 6(4):337-41.
32. Звонков Е.Е. Первичные экстранодальные В-клеточные лимфатические опухоли: клиника, диагностика, лечение. Докторская диссертация. М., 2009.  [Zvonkov EE.  Primary extranodal B-cell lymphomas: clinic, diagnosis and treatment. Doctoral dissertation. Moscow, 2009. (In Russ.)].
33. Wachters C. A rare case of breast malignancy associated with hypercalcemia: double hit lymphoma. Belg J Med Oncol. 2017; 11(3):122-125.
34. Dongfeng Zeng, Aakash Desai, Fangfang Yan, Tiejun Gong, Haige Ye,  Makhdum Ahmed. Challenges and Opportunities for High-grade 
B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). American Journal of Clinical Oncology. 2018. 
35. Landsburg DJ, Falkiewicz MK, Maly J et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017; 35(20):2260-2267.
36. Звонков Е.Е., Морозова А.К., Кравченко С.К. Лечение взрослых больных первичной диффузной В-крупноклеточной лимфосаркомой желудка по модифицированной программе NHL-BFM-90. Программное лечение заболеваний системы крови. Под ред. 
В.Г. Савченко, академика РАН. М.: Практика, 2012; т. II: 659-678. 
[Zvonkov EE, Morozova AK, Kravchenco CK.  Treatment of adults with primary diffuse large B-cell lymphosarcoma of the stomach according to the  modified program NHL-BFM-90. Program treatment of diseases of the blood system.  Under the editorship of 
V.G. Savchenko, M.: Praktica, 2012; V II: 659-678. (In Russ.)].
37. Звонков Е.Е., Морозова А.К., Кравченко С.К., Магомедова А.У., Илюшкина Е.А., Красильникова Б.Б., Гемджян Э.Г., Воробьев В.И., Кременецкая А.М., А.И. Воробьев А.И. Восьмилетний опыт применения модифицированной программы NHL-BFM-90 в лечении взрослых больных первичной диффузной В-крупноклеточной лимфомой желудка. Гематология и трансфузиология. 2012; (3):47. [Zvonkov EE, Morozova AK, Kravchenco CK, Magamedova AY, Ilushkina EA, Krasilnikova BB, Gemgian EG, Vorobiov VI, Kremenezkaia AM, Vorobiov AI. Eight-year experience in the use of the modified NHL-BFM-90 program in the treatment of adult patients with primary diffuse large B-cell lymphoma of the stomach. Hematology and transfusiology. 2012; (3):47. (In Russ.)].
38. Гаврилина О.А., Габеева Н.Г., Морозова А.К., Сидорова А.А., Звонков Е.Е. Роль высокодозной химиотерапии и трансплантации аутологичных стволовых клеток крови у пациентов с диффузной В-крупноклеточной лимфомой. Терапевтический архив. 2013; 85(7): 90-97. [Gavrilina OA, Gabeeva NG, Morozova AK, Sidorova AA, Zvonkov  EE. Role of high-dose chemotherapy and autologous stem cell  transplantation in patients with diffuse large B-cell lymphoma. Terapevticheskii arkhiv. 2013; 85(7): 90-97. (In Russ.)].

________________________________________________

1. Aukema SM, Siebert R, Schuuring E, van Imhoff  GW, Kluin-Nelemans  HC, Boerma E-J, Kluin PM. Double-hit B-cell lymphomas. Blood. 2011 (24 February);  117(8).
2. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. IARC, Lyon, 2016. 
4. Zhou K, Xu D, Cao Y, Wang J, Yang Y, Huang M, C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. PLoS One. 2014; 9(4):e95020. 
5. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y & Miura I. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009; 94, 935-943. 
6. Horn H, Ziepert M, Becher C et al., MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121(12):2253-63. 
7. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L et al., Double-hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014; 166:891-901. 
8. de Jongea AV,  Roosmaa TJA,  Houtenbosb I,  Vasmeld WLE,  van de Heme K,   de Boerf  JP, van Maaneng T, Lindauer-van der Werfh G, Beekerc A, Timmersi GJ, Schaarj CG, Soesank M, Poddighel PJ, de Jongm D. M.E.D., Chamuleaua.  Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature. European Journal of Cancer. 2016; 55: 140-146. 
9. Petrich AM, Gandhi M, Jovanovic B et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124 (15).
10. Sun H, Savage KJ, Karsan A et al. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Сlinical Lymphoma, Myeloma & Leukemia, 2015 June.
11. Cuccuini W, Briere J, Mounier N et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012; 119:4619-4624. 
12. Herrera AF, Mei M, Low L et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017; 35:24-31. 
13. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Kuppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014; 99:726-35.
14. [Gabeeva NG, Koroleva DA,  Beliaeva AV, Chernova NG, Kuzmina LA,  Sudarikov AB, Obuchova TN, Kovrigina AM, Zvonkov EE, Savchenko VG. Diffuse large B-cell lymphoma with concomitant  rearrangement of genes c-MYC and BCL-6 with primary cutaneous involvement: a case report  and review of literature. Terapevticheskii arkhiv. 2017; 89(7):85-92. (In Russ.)].
15. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T et al. and the Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB), MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98:1554-62.
16. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequencespecific transcriptional repressor. Proc Natl Acad Sci USA. 1996; 93:6947-6952.
17. Iqbal J, Greiner TC, Patel K, Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007 November; 21(11): 2332-2343.
18.  [Obuchova TN, Barax EA, Lorie UU, Chernuch CA, Kolocheinova TI, Petrova GD, Nesterava EC, Rimachevskaia EV, Semenova AA, Magamedova AY, Zvonkov EE, Parovichnicova EN, Alimova GA, Kleina BD, Kovrigina AM, Kaplanskaia IB, Vorobov IA, Lugovskaia SA, Tupicin NN, Krafchenco CK, Domracheva EV. «Double-hit» lynphomas. Hematology and transfusiology. 2012; 57(S3):17. (In Russ.)].
19. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463: 88-92. 
20. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459:717-721. 
21. Wei-Ge Wang, Xiang-Nan Jiang, Ze-Bing Liu, Xiao-Yan Zhou, Xiao-Qiu Li,  MYC Protein–positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway. Am J Surg Pathol. 2017; 41(4). 
22. Wilson WH, Young RM et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature medicine. 2015; 21(8).
23. Younes A, Thieblemont C et al. Combination of ibrutinib with rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014; 15: 1019-26. 
24. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:1937-1947.
25. Johnson-Farley N, Veliz J, Bhagavathi S et al. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells. Leuk Lymphoma. 2015; 56:2146-2152.
26. Borthakur G, Dawson MA, Stein EM et al. A phase I/II openlabel, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies. Blood. 2016; 128:5223. 
27. Nabhan C, Karrison T, Kline J et al. Prospective phase I multicenter trial incorporating lenalidomide (LEN) into dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in patients with double hit (DHL) or double expressing (DEL) lymphomas: final results. Blood. 2016; 128:4191.
28. Lindsleya RC, LaCascea AS. Biology of Double-Hit B Cell Lymphomas. Curr Opin Hematol. 2012 July; 19(4):299-304.
29. Sarkozy C, Traverse-Glehen A, Coiffier B, Double-hit and double-protein-expression lymphomas:aggressive and refractory lymphomas. Lancet Oncol. 2015; 16: 555-67.
30. [Chernova NG, Zvonkov EE, Kovrigina AM, Sudarikov AB, Badmazhapova DS, Gabeeva NG, Obukhova TN, Karagyulyan SR, Savchenko VG.  Breast implant-associated anaplastic large-cell lymphoma: A case report and a review of literature. Terapevticheskii arkhiv. 2017; 89(7):93-98. (In Russ.)].
31. Ryan GF1, Roos DR, Seymour JF. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma. 2006 Jan; 6(4):337-41.
32.[Zvonkov EE.  Primary extranodal B-cell lymphomas: clinic, diagnosis and treatment. Doctoral dissertation. Moscow, 2009. (In Russ.)].
33. Wachters C. A rare case of breast malignancy associated with hypercalcemia: double hit lymphoma. Belg J Med Oncol. 2017; 11(3):122-125.
34. Dongfeng Zeng, Aakash Desai, Fangfang Yan, Tiejun Gong, Haige Ye,  Makhdum Ahmed. Challenges and Opportunities for High-grade 
B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). American Journal of Clinical Oncology. 2018. 
35. Landsburg DJ, Falkiewicz MK, Maly J et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017; 35(20):2260-2267.
36. [Zvonkov EE, Morozova AK, Kravchenco CK.  Treatment of adults with primary diffuse large B-cell lymphosarcoma of the stomach according to the  modified program NHL-BFM-90. Program treatment of diseases of the blood system.  Under the editorship of 
V.G. Savchenko, M.: Praktica, 2012; V II: 659-678. (In Russ.)].
37. [Zvonkov EE, Morozova AK, Kravchenco CK, Magamedova AY, Ilushkina EA, Krasilnikova BB, Gemgian EG, Vorobiov VI, Kremenezkaia AM, Vorobiov AI. Eight-year experience in the use of the modified NHL-BFM-90 program in the treatment of adult patients with primary diffuse large B-cell lymphoma of the stomach. Hematology and transfusiology. 2012; (3):47. (In Russ.)].
38.  [Gavrilina OA, Gabeeva NG, Morozova AK, Sidorova AA, Zvonkov  EE. Role of high-dose chemotherapy and autologous stem cell  transplantation in patients with diffuse large B-cell lymphoma. Terapevticheskii arkhiv. 2013; 85(7): 90-97. (In Russ.)].

Е.Е. ЗВОНКОВ, Н.Г. ГАБЕЕВА, А.В. БЕЛЯЕВА, Д.А. КОРОЛЕВА, А.К. СМОЛЬЯНИНОВА, Т.Н. ОБУХОВА, А.М. КОВРИГИНА, В.Г. САВЧЕНКО 

ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия

________________________________________________

E.E. ZVONKOV, N.G. GABEEVA, A.V. BELIAEVA, D.A. KOROLEVA, A.K. SMOLIANINOVA, T.N. OBUKHOVA, A.M. KOVRIGINA, V.G. SAVCHENKO

National Research Center for Hematology, Russian Federation, Moscow, Russia